NDAC Denavir review
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee will meet at Bethesda Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md., at 8:30 a.m. Dec. 1 to consider SmithKline Beecham's switch application for topical penciclovir 1% cream for the treatment of recurrent labial herpes, or cold sores, in immunocompetent adults. The open public hearing will be held from 1-2 p.m. To participate, contact Rhonda Stover or Sandra Titus at (301) 827-7001. Sandra Titus, PhD, formerly of CDER's Office of Compliance, is new executive secretary for NDAC. Tentative meeting dates for 1999 are Feb. 18-19, April 15-16, July 19-20, Oct. 18-19 and Dec. 2-3
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning